Om

Cybin Inc. Common Stock represents Cybin Inc., a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions. The company is advancing a pipeline of investigational treatments designed to address psychiatric and neurological disorders, with work centered on proprietary compounds, drug delivery systems, and clinical research programs. Its current activities include late-stage and mid-stage development efforts for therapies targeting major depressive disorder and generalized anxiety disorder, alongside earlier-stage programs exploring additional neuropsychiatric uses. Cybin’s business is rooted in research and development, supported by partnerships and scientific collaborations that help advance its therapeutic platform. The company is headquartered in Toronto, Canada, and operates within the biotechnology and pharmaceutical research sectors, where it is known for its focus on next-generation mental health treatment options.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I HELUS PHARMA MED ENDAVU: Køb Helus Pharma ($R7E) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Helus Pharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.